Adverse Drug Reaction Hospital Costs in Africa Reach Thousands of Dollars
A systematic review of African cost-of-illness studies reveals that adverse drug reactions impose substantial economic burdens, driven primarily by hospitalization ...
A systematic review of African cost-of-illness studies reveals that adverse drug reactions impose substantial economic burdens, driven primarily by hospitalization ...
A dynamic health economic model demonstrates that introducing subcutaneous ocrelizumab for relapsing multiple sclerosis could save Italian hospital centers approximately ...
A multicriteria decision analysis integrating clinical trial synthesis, safety metrics, and acquisition costs found ambrisentan ranked highest overall among three ...
A cost-effectiveness analysis indicates that belantamab requires an approximate 98 percent price reduction from its United States list price to ...
A health economic modeling study indicates that prophylactic letermovir for high-risk adult kidney transplant recipients generates modest net healthcare savings ...
An updated horizon-scanning analysis projects that annual public spending on multiple sclerosis therapies in Italy will decline from 784 million ...
A lifetime semi-Markov cohort model indicates that adjuvant ribociclib combined with an aromatase inhibitor is cost-effective for stage II and ...
A budget impact model projects that a cfRNA test-and-treat strategy for preeclampsia could save US commercial health plans $36.6 million ...
A deterministic budget impact model shows introducing bimekizumab as a first-line therapy for moderate-to-severe plaque psoriasis generates substantial five-year savings ...
Researchers propose reproducible therapeutic surplus as a framework linking immediate clinical benefit to long-term health system capacity and uncertainty governance.
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine